Home › NDC Lookup › RxCUI directory › RxCUI 2680366

Nirogacestat 150 MG Oral Tablet — RxCUI 2680366

RxNorm drug concept · Semantic clinical drug
RxCUI 2680366 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2680366
Official nameNirogacestat 150 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asnirogacestat 150 MG (equivalent to nirogacestat HBr 199.574 MG) Oral Tablet
FDA products mapped2
Package NDCs mapped2
Reported Medicaid activity (SDUD)611 prescriptions · 10 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Nirogacestat: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Nirogacestat, sold as Ogsiveo, treats adults whose desmoid tumors are growing and need whole-body treatment. It works by blocking a signaling pathway called Notch that can drive tu...
  • You take the tablet by mouth twice a day, with or without food. Swallow it whole and do not crush, chew or break it. If you miss a dose or vomit, skip it and take your next dose at...
  • Diarrhea is the most common, so ask your doctor about anti-diarrheal medicine. Rash, nausea, fatigue, mouth sores, headache and stomach pain are also common. Call your doctor if di...
  • Yes. It can cause ovarian toxicity, such as missed periods or early menopause, and may impair fertility in females and males. Tell your doctor about period changes, hot flashes or...
📖 Read our full Nirogacestat guide →

🕸️ Concept Web — How Nirogacestat 150 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Nirogacestat 150 MG Oral Tablet RxCUI 2680366

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Nirogacestat 2670631
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Ogsiveo 2670638
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Nirogacestat Oral Tablet 2670636
    • Nirogacestat Oral Product 2670634
    • Nirogacestat Pill 2670635
    • Nirogacestat Oral Tablet [Ogsiveo] 2670642
    • Ogsiveo Oral Product 2670640
    • Ogsiveo Pill 2670641
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

  5. Packs 2

    Fixed collections of drugs packaged and sold together, like dose packs.

Showing up to 8 concepts per family — 15 of 16 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brand-Name Concepts

📦 FDA Products & Package NDCs

2 products · 2 package NDCs
2 package NDCs map to RxCUI 2680366 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
82448-0100-14 14 TABLET, FILM COATED in 1 BLISTER PACK (82448-100-14) OGSIVEO SpringWorks Therapeutics, Inc. 2023-11-27
82448-0150-14 14 TABLET, FILM COATED in 1 BLISTER PACK (82448-150-14) OGSIVEO SpringWorks Therapeutics, Inc. 2023-11-27
Observed labelers: SpringWorks Therapeutics, Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.